NCT06247150Recruiting
Tissue Immune Landscape of Graft Versus Host Disease After Allogeneic Stem Cell Transplantation (TIL-GVHD)
Source: ClinicalTrials.gov · Last updated 16 Jul 2026
Brief summary (registry, in English)
Graft versus Host Disease (GVHD) is frequent after allogeneic stem cell transplantation (alloSCT). GVHD occurs following 2 patterns : acute GVHD (aGVHD) or chronic GVHD (cGVHD). The latter occurs in nearly 50% of patients and its pathogenesis remains poorly understood. Previous translational studies have delineated biological immune dysregulation involved in cGVHD and facilitated the development of new drug and therapeutic strategies. New aspects of T and B cells collaboration in the context of cGVHD using blood description of a key player called TFH, classicaly involved in germinal center reaction, were previously uncovered (Forcade et al, Blood 2016). Previous studies in the context of auto-immune inflammation (lupus nephritis) or organ transplant rejection, suggested that target tissue could contain accessory lymphoid structures (TLS). The description of such structures in cGVHD target tissue would give the opportunity to directly analyze immune key player involved the pathogenesis of cGVHD.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 70 (estimated)
- First submitted
- 30 Jan 2024
- Start date
- 21 May 2024
- Primary completion date
- May 2028
- Lead sponsor
- University Hospital, Bordeaux
- NCT number
- NCT06247150
What you commit to
- Study type: Interventional
- Planned participants: 70
- From 21 May 2024 to the primary completion date, May 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Systemic therapy using steroids over 15mg/d of Prednisone ; and/or the use of other systemic agent introduced in the last month ;
Other
- Patient below 18 yo or unable to give consent ;
- Haemorrhagic risk of biopsy anticipated ;
- Absence of patient agreement for the study
Who the study is looking for
- Patient \> 18 yo ;
- Having undergone an allogeneic stem cell tranplant ;
- 2 groups of patients will be eligible
- showing evidence of primary cGVHD or occuring after Donor Lymphocyte Infusion
- in the case of first occurrence of cGVHD, in the absence of any new systemic therapy ;
- in the case of recurrent cGVHD, steroid dose has to be below 15mg/day of Prednisone ;
- Having read, understood and signed an informed consent of the study;
- With social security affiliation;
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU de Bordeaux, Service d'Hématologie Clinique et Thérapie Cellulaire Coordinator of this site? Confirm its status | Pessac | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.